
Oramed Pharmaceuticals Inc.: updates and filings
Price
$3.57
November 20, 2026Market cap $155M
What Ploutos Investor adds for Oramed Pharmaceuticals
Part of Ploutos Investor, €9.99 a month
- The full history: 9 fiscal years, from FY2016
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The reported profit is far larger than a business usually earns on its market value, which usually means one-off or accounting gains. We leave out the P/E and the earnings yield.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
An estimate from when it has reported before, and the timing has varied a little. The company announces the date itself.
November 2026
September 2026
March 2026
February 2026
January 2026
December 2025
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 19, 2026Other material eventsForm8-K
- Nov 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 12, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Sep 17, 2026Shareholder voteForm8-K
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 10, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 3, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Aug 3, 2026Additional annual meeting materialFormDEFA14A
- Aug 3, 2026Annual meeting proxy statementFormDEF 14A
- Jul 22, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Jun 30, 2026Amended articles or bylaws, other material eventsForm8-K
- Jun 29, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jun 17, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- May 19, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 15, 2026Notice that the quarterly report will be filed lateFormNT 10-Q
- May 15, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- May 14, 2026Over-5% holder statement (active)FormSCHEDULE 13D
- Mar 31, 2026Material agreement entered, acquisition or disposal of assetsForm8-K
- Mar 26, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Feb 20, 2026Material agreement enteredForm8-K
- Feb 19, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Feb 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Feb 9, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jan 29, 2026Over-5% holder statement (active)FormSCHEDULE 13D
- Jan 14, 2026Material agreement entered, other material eventsForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 19, 2026 | 8-K | Other material events | Document |
| Nov 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 12, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Sep 17, 2026 | 8-K | Shareholder vote | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 10, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 3, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Aug 3, 2026 | DEFA14A | Additional annual meeting material | Document |
| Aug 3, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Jul 22, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Jun 30, 2026 | 8-K | Amended articles or bylaws, other material events | Document |
| Jun 29, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jun 17, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| May 19, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 15, 2026 | NT 10-Q | Notice that the quarterly report will be filed late | Document |
| May 15, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| May 14, 2026 | SCHEDULE 13D | Over-5% holder statement (active) | Document |
| Mar 31, 2026 | 8-K | Material agreement entered, acquisition or disposal of assets | Document |
| Mar 26, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Feb 20, 2026 | 8-K | Material agreement entered | Document |
| Feb 19, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Feb 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Feb 9, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jan 29, 2026 | SCHEDULE 13D | Over-5% holder statement (active) | Document |
| Jan 14, 2026 | 8-K | Material agreement entered, other material events | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Nov 29, 2002. Of its note and share prospectuses (424B, FWP), the newest 40 of 65.
The full analysis
What do Oramed Pharmaceuticals's filings show?
The filings are where every one of Oramed Pharmaceuticals's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.